What treatment options are available for a 44-year-old perimenopausal woman with low libido, and is testosterone replacement therapy indicated; if so, what delivery modalities can be used?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Low Libido in a 44-Year-Old Perimenopausal Woman

For a 44-year-old perimenopausal woman with low libido, testosterone replacement therapy can be considered as a treatment option after comprehensive biopsychosocial assessment, though the evidence is strongest for postmenopausal women with hypoactive sexual desire disorder (HSDD). 1

Understanding the Clinical Context

Your patient is in perimenopause, which represents a transitional phase where the evidence base is less robust than for postmenopausal women. The 2014 Endocrine Society guideline specifically addresses postmenopausal women, noting that transdermal testosterone at 300 µg/day significantly improved satisfying sexual events (from 3 to 5 per month), with improvements in arousal, pleasure, orgasm, and reduced personal distress in both surgically and naturally menopausal women 1. However, limited data also support use in late reproductive age premenopausal women 2.

Key Diagnostic Considerations Before Treatment

Before considering testosterone therapy, you must:

  • Rule out modifiable factors: relationship problems, mental health disorders (depression, anxiety), medications (SSRIs, oral contraceptives, oral estrogen), chronic medical conditions, and inadequate estrogen replacement if already on hormone therapy 1, 3
  • Confirm this is HSDD: persistent low desire causing personal distress, not simply age-related changes in sexual frequency 1, 3
  • Assess for contraindications: hormone-sensitive breast cancer (relative contraindication), untreated cardiovascular risk factors 4, 3

Treatment Algorithm

First-Line Approach: Address Underlying Factors

  1. Optimize estrogen status: If she has vasomotor symptoms or other menopausal symptoms, ensure adequate estrogen replacement first, as testosterone works best with adequate estrogen 1, 4
  2. Review medications: Oral estrogen increases SHBG and may worsen androgen deficiency; consider transdermal estrogen instead 1
  3. Biopsychosocial assessment: Address relationship issues, stress, body image concerns through counseling 3, 5

Second-Line: Testosterone Therapy

If low libido persists despite adequate estrogen replacement and addressing modifiable factors, testosterone therapy is reasonable 1, 3, 2.

Testosterone Replacement: Specific Recommendations

Baseline Testing

  • Measure total testosterone (though not for diagnosis of HSDD, but for monitoring) 3, 2
  • Do NOT use testosterone levels to diagnose HSDD - this is a clinical diagnosis based on symptoms and distress 1, 3, 2
  • Screen for cardiovascular risk factors, lipid profile 5

Available Modalities (Critical Limitation)

There are NO FDA-approved testosterone formulations for women in the United States 3, 6, 2, 7. This creates a significant treatment gap. Your options are:

1. Transdermal Testosterone (Preferred Route)

  • Dosing: Aim for physiologic premenopausal levels - approximately 300 µg/day transdermal 1
  • Formulation: Use male testosterone gel at 1/10th the male dose 3, 8
    • Example: Male gel 1.62% delivers 20.25 mg per pump actuation 9
    • For women: Use approximately 1/10th of male dose to achieve ~300 µg/day
  • Application: Upper arms/shoulders, covered by clothing after drying 9
  • Evidence: This is the best-studied formulation with moderate-to-high quality evidence for efficacy 1

2. Testosterone Cream (Compounded)

  • Caution: Compounded products lack standardized quality control and cannot be routinely recommended unless approved products unavailable 3, 2
  • If used, must be from pharmacy compliant with Good Manufacturing Practice 3
  • Recent pilot data showed improvements in mood and cognition with testosterone cream/gel in perimenopausal women 10

3. Subcutaneous Testosterone Implants

  • Available in some countries (UK, Australia) but not widely in US 4
  • Risk: Often deliver supraphysiologic levels and are NOT recommended 3
  • Should be limited to 24 months if used 4

4. NOT Recommended

  • Testosterone pellets/injections: Result in supraphysiologic levels 3
  • Oral methyltestosterone: Potential liver toxicity, less favorable safety profile 11
  • DHEA: Insufficient evidence for benefit in sexual function 1

Monitoring Protocol

Critical monitoring steps 3, 2:

  1. Baseline: Total testosterone level, clinical assessment
  2. 3-6 weeks: Repeat testosterone level to ensure physiologic premenopausal range (approximately 300-500 ng/dL total testosterone)
  3. Every 6 months:
    • Testosterone level (maintain in physiologic range)
    • Assess for androgen excess: acne, hirsutism, voice changes, clitoromegaly
    • Clinical response assessment
  4. If no benefit by 6 months: Discontinue therapy 3

Expected Outcomes

Based on the strongest evidence 1:

  • Modest improvement: Increase of approximately 1-2 satisfying sexual events per month
  • Improvement in multiple domains: desire, arousal, orgasm, reduced distress
  • Placebo response is substantial: 40-48% reduction in distress with placebo alone
  • Effect size is moderate: Not a dramatic transformation

Safety Considerations

Short-term safety (up to 24 months) 1, 3:

  • No increased breast cancer risk with physiologic doses
  • No serious cardiovascular events in trials
  • Androgenic side effects (acne, hirsutism) are mild and reversible
  • However: Long-term safety data beyond 24 months are lacking 1, 3

Special concern for your perimenopausal patient 4:

  • Data are primarily from postmenopausal women
  • Impact on breast cancer risk in premenopausal/perimenopausal women is unknown
  • Should be used with caution and informed consent about limited data in this age group

Critical Pitfalls to Avoid

  1. Using testosterone without adequate estrogen: Testosterone works best with concurrent estrogen therapy 1
  2. Supraphysiologic dosing: Using male doses or pellets leads to excessive levels and side effects 3
  3. Diagnosing based on testosterone levels: HSDD is a clinical diagnosis; low testosterone levels do NOT define the condition 1, 3, 2
  4. Ignoring psychosocial factors: Testosterone alone without addressing relationship/psychological issues is insufficient 3, 5
  5. Inadequate monitoring: Must check levels to avoid supraphysiologic dosing 3, 2
  6. Secondary exposure risk: Warn about transfer to children/partners from application sites 9

Practical Implementation

Informed consent discussion must include 3, 6, 2:

  • Off-label use (no FDA-approved formulation for women)
  • Modest expected benefit (1-2 additional satisfying events/month)
  • Unknown long-term safety beyond 2 years
  • Need for ongoing monitoring
  • Androgenic side effects
  • Cost (often not covered by insurance for this indication)

Trial period approach 3, 2:

  • Start transdermal testosterone at physiologic dose
  • Reassess at 3-6 months
  • If no improvement by 6 months, discontinue
  • If beneficial, continue with 6-month monitoring
  • Consider limiting duration to 24 months given lack of long-term data

Alternative/Adjunctive Options

If testosterone is not appropriate or desired 5:

  • Psychosexual therapy: Cognitive-behavioral approaches for HSDD
  • Optimize general health: Exercise, sleep, stress management
  • Address vasomotor symptoms: May improve overall quality of life and indirectly affect libido
  • Vaginal estrogen: If genitourinary symptoms contribute to sexual dysfunction

The evidence supports cautious use of transdermal testosterone in your perimenopausal patient with persistent HSDD after addressing modifiable factors, using off-label male formulations at 1/10th the dose, with close monitoring and informed consent about limited long-term safety data in this population 1, 3, 2.

References

Guideline

androgen therapy in women: a reappraisal: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2014

Guideline

global consensus position statement on the use of testosterone therapy for women.

The Journal of clinical endocrinology and metabolism, 2019

Guideline

treatment of symptoms of the menopause: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2015

Research

Testosterone for Treating Female Sexual Dysfunction.

Clinical obstetrics and gynecology, 2025

Guideline

american association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.